Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 21;24(6):5938.
doi: 10.3390/ijms24065938.

Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience

Walid Shalata  1 , Jeremy Zolnoorian  2 , Gabrielle Migliozzi  2 , Ashraf Abu Jama  1 , Yulia Dudnik  1 , Ahron Yehonatan Cohen  1 , Amichay Meirovitz  1 , Alexander Yakobson  1
Affiliations

Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience

Walid Shalata et al. Int J Mol Sci. .

Abstract

Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profiles, very little exists about the long-term effects of pembrolizumab. We compiled all patients with NSCLC who were treated with pembrolizumab at our institution and had progression-free survival (PFS) of at least 2 years during or after the treatment period. Within this group, we examined the long-term rates of PFS and overall survival (OS), side effect profiles, treatment, and overall disease course up to 60 months after starting treatment. This study included 36 patients with median (range) follow up times from treatment initiation in months as follows: 36 (28-65) overall; 39.5 (28-65) for adenocarcinoma; and 36 (30-58) for squamous cell carcinoma. The median (range) of OS and PFS (months) was comparable for adenocarcinoma, 36 (23-55); and squamous cell carcinoma, 35.5 (28-65). Overall, pembrolizumab shows remarkable long-term safety and efficacy in NSCLC patients. In patients who show an initially strong response and can make it to 24 months of PFS, disease progression after this period seems increasingly unlikely.

Keywords: Keytruda; PD-1; immune checkpoint inhibitors; lung cancer; non-small cell lung cancer; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival and progression-free survival in the intention-to-treat population.
Figure 2
Figure 2
Overall survival and progression-free survival for patients who had treatment stopped early due to adverse effects.
Figure 3
Figure 3
Adverse events of any cause in the as-treated population.
Figure 4
Figure 4
Time to best response.
See this image and copyright information in PMC

References

    1. Shalata W., Yakobson A., Weissmann S., Oscar E., Iraqi M., Kian W., Peled N., Agbarya A. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience. Oncology. 2022;100:467–474. doi: 10.1159/000525188. - DOI - PubMed
    1. Rafei H., El-Bahesh E., Finianos A., Nassereddine S., Tabbara I. Immune-based Therapies for Non-small Cell Lung Cancer. Anticancer Res. 2017;37:377–387. doi: 10.21873/anticanres.11330. - DOI - PubMed
    1. Szeto C.H., Shalata W., Yakobson A., Agbarya A. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future. J. Clin. Med. 2021;10:5614. doi: 10.3390/jcm10235614. - DOI - PMC - PubMed
    1. Thai A.A., Solomon B.J., Sequist L.V., Gainor J.F., Heist R.S. Lung cancer. Lancet. 2021;398:535–554. doi: 10.1016/S0140-6736(21)00312-3. - DOI - PubMed
    1. Elias R., Morales J., Presley C. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Curr. Oncol. Rep. 2017;19:62. doi: 10.1007/s11912-017-0619-0. - DOI - PubMed